Regeneron Pharmaceuticals (NasdaqGS:REGN) recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals, acquiring rights for a dual GLP-1/GIP receptor agonist, HS-20094.

The acquisition of HS-20094 enhances Regeneron’s portfolio of obesity and metabolic programs, which aim to improve the quality of weight loss and address long-term health comorbidities.

Additionally, Regeneron has entered into a licensing agreement with Hansoh Pharmaceuticals for the obesity drug candidate HS-20094 ... $1.93 billion. This acquisition is expected to enhance ...

Additionally, Regeneron has entered into a licensing agreement with Hansoh Pharmaceuticals for the obesity drug candidate HS-20094, with an upfront payment of $80 million and potential future ...

Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Regeneron Pharmaceuticals (REGN ... Hong Kong and Macau for a dual GLP-1/GIP receptor agonist, HS-20094, currently in Phase 3 testing.

has been named the winner of won the top award in the Regeneron Science Talent Sea Achyuta Rajaram 2024, America’s oldest and most prestigious science and math competition for high school ...

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual ...